Zyversa TherapeuticsZVSA
13F holders, Q2 2024 (June 30)4holders
$3.76avg. 13F price*
At the end of Q2 2024, 4 institutions reported holding Zyversa Therapeutics Inc. (ZVSA) in their 13F filings. The largest holders were ADAR1 Capital Management, LLC ($36K), Tower Research Capital LLC (TRC) ($3K) and Bank of America Corp. ($26).
- Company
- Zyversa Therapeutics Inc.
- CUSIP
- 98987D300
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $39K |
| Exits | 0 | $0 |
Ownership 4 holders
| ADAR1 Capital Management, LLC | 0.01% | New | 9,598 | $36K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 699 | $3K |
| Bank of America Corp. | 0.00% | New | 7 | $26 |
| JPMorgan Chase & Co. | 0.00% | New | 1 | $4 |
"% of holder's portfolio" is ZVSA's weight in each manager's 13F, not the share of Zyversa Therapeutics Inc. the manager owns.